AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

The present study will investigate the safety, tolerability and spectrum of side effects of AGS-1C4D4. As such, this study will characterize the dose limiting toxicities (DLT) and potentially the maximum tolerated dose (MTD) of AGS-1C4D4 in patients with advanced HRPC.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Agensys, Inc.
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Patient has hormone-refractory metastatic prostate cancer

Exclusion Criteria:

• Patient has had chemotherapy, radiotherapy, or biological therapy within the past 4 weeks or has not recovered from side effects

• Patient is currently participating or has participated in an investigational study within the past 30 days

• Patient has illness or circumstance that could limit compliance with the study requirements

• Patient uses illicit drugs or had a recent history of drug or alcohol abuse within the last year

• Patient has Hepatitis B or C